Covestor’s NovoCure NVCR Stock Holding History

Covestor’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5K	Buy	475 +73	+18%	+$912	﹤0.01%	1812
2025 Q4	$5K	Hold	402	–	–	﹤0.01%	1848
2025 Q3	$5K	Sell	402 -1	-0.2%	-$13	﹤0.01%	1853
2025 Q2	$7K	Sell	403 -1	-0.2%	-$17	﹤0.01%	1714
2025 Q1	$7K	Sell	404 -222	-35%	-$5.04K	﹤0.01%	1672
2024 Q4	$19K	Buy	626 +1	+0.2%	+$21	0.01%	1222
2024 Q3	$10K	Hold	625	–	–	0.01%	1568
2024 Q2	$11K	Buy	625 +2	+0.3%	+$35	0.01%	1477
2024 Q1	$10K	Sell	623 -1	-0.2%	-$15	0.01%	1599
2023 Q4	$9K	Buy	624 +387	+163%	+$5.18K	0.01%	1648
2023 Q3	$4K	Buy	237 +131	+124%	+$3.78K	﹤0.01%	1746
2023 Q2	$4K	Sell	106 -1	-0.9%	-$62	﹤0.01%	1729
2023 Q1	$6K	Buy	107 +2	+2%	+$160	0.01%	1526
2022 Q4	$8K	Hold	105	–	–	0.01%	1428
2022 Q3	$8K	Buy	105 +103	+5,150%	+$8.03K	0.01%	1352
2022 Q2	$0	Sell	2 -2	-50%	-$151	﹤0.01%	2210
2022 Q1	$0	Hold	4	–	–	﹤0.01%	2324
2021 Q4	$0	Buy	+4	New	+$402	﹤0.01%	2233

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Covestor's NVCR Position: Q1 2026 in Review

Covestor increased its NovoCure (NVCR) stake by 18% in Q1 2026, buying an estimated $912 and bringing the position to 475 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #1812.

Covestor first reported a position in NVCR in Q4 2021 and has held it in 18 quarters since. The position peaked at $19K in Q4 2024. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Covestor held 475 shares of NovoCure worth $5K as of Q1 2026.
Covestor bought 73 NovoCure shares in Q1 2026, an estimated $912.
NovoCure made up ﹤0.01% of Covestor's portfolio in Q1 2026, its #1812 holding.
Covestor first reported a position in NovoCure in Q4 2021 and has held it in 18 quarters since.
Covestor's NovoCure position peaked at $19K in Q4 2024.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.